| Q88883573 | A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus |
| Q57243651 | A Randomized Controlled Trial of Belimumab for the Treatment of Active Systemic Lupus Erythematosus |
| Q40345289 | A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings |
| Q38944472 | A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus. |
| Q99710372 | A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab |
| Q92656085 | A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease |
| Q37378350 | A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus |
| Q28254310 | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus |
| Q49359821 | A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea |
| Q47116737 | A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
| Q34394509 | A rare case of prototheca algaemia in a patient with systemic lupus erythematosus and recent belimumab infusion |
| Q92727505 | A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE |
| Q43961548 | A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. |
| Q91720943 | Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter |
| Q100386043 | Adding belimumab improves lupus nephritis |
| Q92559285 | Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association |
| Q53071532 | An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity. |
| Q37850690 | An update on belimumab for the treatment of lupus |
| Q64045422 | Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab |
| Q35816153 | Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis |
| Q64088568 | Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab |
| Q95304723 | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
| Q90795990 | B cell alterations during BAFF inhibition with belimumab in SLE |
| Q102056363 | B-cell depletion or belimumab or voclosporin for lupus nephritis? |
| Q52639397 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. |
| Q39132754 | BUDGET IMPACT ANALYSIS OF BELIMUMAB IN TREATING SYSTEMIC LUPUS ERYTHEMATOSUS. |
| Q30645037 | Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials |
| Q84324262 | Belimumab (Benlysta) for systemic lupus eruthematosus |
| Q35958642 | Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus |
| Q93190907 | Belimumab Concentrations in Maternal Serum and Breast Milk During Breastfeeding and the Safety Assessment of the Infant: A Case Study |
| Q83857457 | Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline |
| Q95598742 | Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines |
| Q92057326 | Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial |
| Q57789612 | Belimumab after rituximab as maintenance therapy in lupus nephritis |
| Q92688703 | Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus |
| Q97646117 | Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents |
| Q50040141 | Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus |
| Q54948758 | Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review. |
| Q34276645 | Belimumab and the clinical data |
| Q50936841 | Belimumab and the measurement of fatigue. |
| Q99554992 | Belimumab as Add-on Therapy in Lupus Nephritis |
| Q39744383 | Belimumab efficacy is 'mild' but market potential still great†: anticipating us approval of the first lupus drug since 1957. |
| Q56907327 | Belimumab en el lupus eritematoso sistémico: una guía para su uso en la práctica diaria |
| Q95314636 | Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients |
| Q84388543 | Belimumab for systemic lupus erythematosus |
| Q24201547 | Belimumab for systemic lupus erythematosus |
| Q28289098 | Belimumab for systemic lupus erythematosus |
| Q95516530 | Belimumab for systemic lupus erythematosus |
| Q46364779 | Belimumab for systemic lupus erythematosus: a practice-based view |
| Q48121915 | Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial |
| Q89241712 | Belimumab for the Treatment of Systemic Lupus Erythematosus (Sle) In Greece: A Cost-Effectiveness and Cost-Utility Analysis |
| Q38014539 | Belimumab for the management of systemic lupus erythematosus |
| Q89282338 | Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients |
| Q50933068 | Belimumab for the treatment of recalcitrant cutaneous lupus. |
| Q86088602 | Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients |
| Q34455827 | Belimumab for the treatment of systemic lupus erythematosus |
| Q102319654 | Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics |
| Q37268312 | Belimumab in Systemic Lupus Erythematosus |
| Q92147284 | Belimumab in kidney transplantation |
| Q95409371 | Belimumab in kidney transplantation |
| Q92147291 | Belimumab in kidney transplantation - Authors' reply |
| Q89129026 | Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial |
| Q100465177 | Belimumab in lupus nephritis |
| Q33437342 | Belimumab in primary antiphospholipid syndrome |
| Q92307444 | Belimumab in refractory organizing pneumonia associated with systemic lupus erythematosus: a case report |
| Q26778277 | Belimumab in systemic lupus erythematosus |
| Q37698526 | Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness |
| Q87218028 | Belimumab in systemic lupus erythematosus -- what can be learned from longterm observational studies? |
| Q88100363 | Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital |
| Q26796486 | Belimumab in systemic lupus erythematosus: a perspective review |
| Q36443781 | Belimumab in systemic lupus erythematosus: an update for clinicians |
| Q38810737 | Belimumab in the management of systemic lupus erythematosus - an update |
| Q101165735 | Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study |
| Q36094045 | Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response |
| Q47815135 | Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy |
| Q97639512 | Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study |
| Q97529168 | Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis |
| Q38005641 | Belimumab is approved by the FDA: what more do we need to know to optimize decision making? |
| Q89460143 | Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient) |
| Q87579928 | Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity |
| Q58760729 | Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients |
| Q91031158 | Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment |
| Q96339082 | Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome |
| Q35954719 | Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus |
| Q91286268 | Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus |
| Q91361736 | Belimumab slows organ damage progression |
| Q38097328 | Belimumab therapy in systemic lupus erythematosus |
| Q92496705 | Belimumab treatment in rhupus: A case report with severe skin involvement |
| Q33695128 | Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study |
| Q37876752 | Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus |
| Q98513236 | Belimumab, a useful alternative therapy in systemic lupus erythematosus serositis |
| Q94707047 | Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases |
| Q49355618 | Belimumab: A Review in Systemic Lupus Erythematosus |
| Q38781470 | Belimumab: First targeted biological treatment for systemic lupus erythematosus |
| Q37809939 | Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus |
| Q37963178 | Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus |
| Q83687622 | Belimumab: a guide to its use in systemic lupus erythematosus |
| Q28676968 | Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis |
| Q81217517 | Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator |
| Q84323277 | Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B |
| Q37964706 | Belimumab: in systemic lupus erythematosus |
| Q34215264 | Belimumab: review of use in systemic lupus erythematosus |
| Q38084687 | Belimumab: targeted therapy for lupus. |
| Q39816043 | Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects |
| Q100303794 | Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab |
| Q36993242 | Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus |
| Q38006643 | Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? |
| Q38095862 | Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy |
| Q91866358 | Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain |
| Q53752806 | Budget Impact Analysis of Belimumab In the Treatment of Patients With Systemic Lupus Erythematosus In Russian Federation. |
| Q98207784 | CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis |
| Q49087015 | Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant |
| Q82732869 | Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects |
| Q96346733 | Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus |
| Q92249194 | Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland |
| Q47946068 | Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study |
| Q46792375 | Clinical response to belimumab in academic clinical practices |
| Q34478853 | Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials |
| Q88758022 | Comment on: New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab |
| Q100533241 | Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study |
| Q88259378 | Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials |
| Q39855585 | Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program |
| Q83107271 | Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? |
| Q58709711 | Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies |
| Q104572682 | Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis |
| Q89241688 | Cost-Effectiveness Analysis of Belimumab In the Treatment of Adult Systemic Lupus Erythematosus (Sle) Patients With Positive Biomarkers In Spain |
| Q37456307 | Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials |
| Q34960458 | Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents |
| Q104505750 | De novo lupus nephritis during treatment with belimumab |
| Q51929640 | Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. |
| Q45237648 | Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus |
| Q91801674 | Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus |
| Q93054164 | Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy |
| Q50950431 | Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. |
| Q91233537 | Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus |
| Q46769274 | Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. |
| Q33803763 | Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study |
| Q91542323 | Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting |
| Q87984753 | Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies |
| Q51655536 | Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. |
| Q36302240 | Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials |
| Q94597729 | Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone |
| Q38791770 | Efficacy and Safety of Belimumab Plus Standard Therapy in Patients With Systemic Lupus Erythematosus: A Meta-analysis |
| Q91151840 | Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study |
| Q88405056 | Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus |
| Q33698040 | Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study |
| Q34369628 | Efficacy and safety data of belimumab in patients with systemic lupus erythematosus |
| Q41514433 | Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study |
| Q28304807 | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial |
| Q38453674 | Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study |
| Q39292745 | Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study |
| Q88787500 | Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial |
| Q57807541 | Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report |
| Q95830647 | Efficacy of Belimumab in Primary Sjögren's Syndrome: A Systematic Review |
| Q99345897 | Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus |
| Q50929875 | Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study. |
| Q95375348 | Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus |
| Q38986342 | Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review |
| Q35568194 | Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis |
| Q35761089 | Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus |
| Q98575505 | Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial |
| Q36672666 | Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab |
| Q90891574 | Established organ damage reduces belimumab efficacy in systemic lupus erythematosus |
| Q89241748 | Evaluation of Use of Belimumab In Clinical Practice Settings (Observe Study) In Spain: Health Resource Utilization and Labour Absenteeism |
| Q95537033 | Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus |
| Q98462463 | Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina |
| Q96639346 | Exposure to Belimumab in the First Trimester of Pregnancy in a Young Woman With Systemic Lupus Erythematosus |
| Q89182146 | Favorable pregnancy outcome in a patient with systemic lupus erythematosus treated with belimumab: A confirmation report |
| Q30490276 | First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. |
| Q28183674 | Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator |
| Q34114253 | Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus |
| Q60913872 | Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies |
| Q37384403 | Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus |
| Q37715948 | Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials |
| Q91554193 | Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus |
| Q94472394 | Influenza vaccine in patients on biological therapy; also with belimumab |
| Q59791466 | Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab |
| Q48504730 | Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States |
| Q96766194 | Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results |
| Q57461365 | Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment |
| Q37121787 | Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care |
| Q91856866 | Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension |
| Q42652135 | Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus |
| Q51738271 | Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. |
| Q36027561 | Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study |
| Q91209271 | Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus |
| Q50118147 | Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients |
| Q98472136 | Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016-2019) |
| Q98179037 | Lupus-associated protein losing enteropathy (LUPLE) complicated by a hypercoagulable state and successfully treated with belimumab |
| Q88204200 | Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy |
| Q96952828 | Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab |
| Q35566828 | Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. |
| Q99725012 | Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia |
| Q84068974 | New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride |
| Q57789397 | OP0302 Significant reductions of pathogenic autoantibodies by synergetic rituximab and belimumab treatment effectively inhibits neutrophil extracellular traps in severe, refractory sle - the synbiose study |
| Q64229203 | Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis |
| Q92745817 | Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial |
| Q47624115 | Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus |
| Q91736978 | Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections |
| Q91782881 | Pharmacogenetic analysis of belimumab fails to identify robust genetic predictors of efficacy in lupus |
| Q103017434 | Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus |
| Q92742184 | Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study |
| Q64069128 | Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol |
| Q48010137 | Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus |
| Q43529181 | Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus |
| Q38230701 | Post-marketing experiences with belimumab in the treatment of SLE patients |
| Q92485957 | Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus |
| Q48302795 | Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus |
| Q55267717 | Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. |
| Q39953054 | Real life experience on the effect of Belimumab in patients with active systemic lupus |
| Q102147270 | Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies |
| Q93271975 | Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA |
| Q56907345 | Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI |
| Q45122982 | Recommendation for use of belimumab for systemic lupus erythematosus |
| Q85275853 | Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody |
| Q37337375 | Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects |
| Q36472640 | Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. |
| Q91720949 | Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter' by Sbeih et al |
| Q102069135 | Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies |
| Q103041670 | Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study |
| Q95552844 | Rituximab-refractory lupus nephritis successfully treated with belimumab |
| Q57789401 | SAT0258 Synergetic b-cell immunomodulation with rituximab and belimumab is clinically effective in severe and refractory systemic lupus erythematosus – the synbiose proof-of-concept study |
| Q91640209 | Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus |
| Q37272264 | Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices |
| Q97546502 | Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan |
| Q97652337 | Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial |
| Q30580226 | Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus |
| Q37077223 | Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus |
| Q95358443 | Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy |
| Q39143034 | Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus |
| Q89351208 | Smoking reduces the efficacy of belimumab in mucocutaneous lupus |
| Q38605480 | Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration |
| Q90935648 | Subcutaneous belimumab in the treatment of systemic lupus erythematosus |
| Q59789656 | Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction |
| Q51164426 | Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment. |
| Q52658159 | Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. |
| Q44050390 | Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman |
| Q89309517 | Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab |
| Q51152275 | Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. |
| Q92308423 | Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab |
| Q104582839 | Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders |
| Q38948425 | Systemic lupus erythematosus exacerbation following cessation of belimumab treatment |
| Q51104713 | Systemic lupus erythematous exacerbation following cessation of belimumab treatment: comments on the article by Furer et al. |
| Q90585211 | The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus |
| Q52595520 | The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. |
| Q35691272 | The discovery and development of belimumab: the anti-BLyS-lupus connection |
| Q42622871 | The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers |
| Q40232762 | The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales |
| Q40183925 | The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. |
| Q94517994 | The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis |
| Q90969407 | The safety of belimumab for the treatment of systemic lupus erythematosus |
| Q40246614 | Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine |
| Q50748403 | Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. |
| Q99554983 | Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis |
| Q50851171 | Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome. |
| Q38258871 | Update on belimumab for the management of systemic lupus erythematosus |
| Q38344444 | Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome |
| Q50231398 | Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus. |
| Q38227435 | Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report |
| Q54113599 | When to use belimumab in SLE. |
| Q95809611 | [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice] |
| Q53493843 | [Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain]. |
| Q80644952 | [Human monoclonal antibody to B-lymphocyte stimulator (belimumab) and humanized anti-LFA-1 monoclonal antibodies (efalizumab)] |
| Q92929406 | [Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study] |
